Antiandrogenic Activity of Riboflavin 5′-Phosphate (FMN) in 22Rv1 and LNCaP Human Prostate Cancer Cell Lines
January 2022
in “
European Journal of Pharmacology
”
Riboflavin 5′-phosphate FMN dihydrotestosterone DHT androgen receptor prostate specific antigen PSA androgen regulated genes ligand binding domain LBD phosphorylation of Akt androgen-related diseases hirsutism benign prostatic hypertrophy acne vulgaris androgenetic hair loss vitamin B2 androgenic alopecia BPH acne
Studysummary In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on sciencedirect.com →